


Startups Harness Cost Benefits Through Time Advantages

Startups in the pharmaceutical and biotechnology industry use innovative pen injection systems throughout the entire product lifecycle. In this whitepaper, you will read how startups benefit!



Companies from the pharmaceutical and biotechnology industries especially, as well as MedTech startups, rely on an experienced development partner – and in this whitepaper, you’ll find out why

MedTech startups and startups in the pharmaceutical and biotechnology sector have to cross a “valley of death” before they get a new product onto the market. Only a few actually make it on their own, and it takes a lot of effort. The up-front costs are enormous: Research work, clinical studies and product development are all very expensive. With an experienced development partner such as Haselmeier, some of the hurdles can be overcome and the time to market maturity significantly reduced.

As a solutions provider for pen injection systems, Haselmeier is the ideal contact for all medicines that are suitable for subcutaneous self-injection using an injection pen. And these medicines are growing in number, since many medications delivered subcutaneously work efficiently, quickly and without putting strain

on the gastrointestinal tract. Haselmeier offers advanced product platforms that are ideal for all phases of clinical development. Information on the medication can be obtained early on, as well as for the later commercial development phase. As the experts in injection-based self-medication, what sets Haselmeier apart is the reliability of its treatment thanks to customized system solutions and it provides inspiration through scalability, convenience and intelligent control and monitoring.

Service and Development Partner for Startups

As one of the leading developers and manufacturers of innovative pen injection systems, Haselmeier offers startups in the MedTech, pharmaceutical and biotechnology sectors the opportunity to benefit from the company’s expertise and in-depth knowledge of the market. That’s because Haselmeier has over 100 years of experience amassed by experts in the development of subcutaneous injection systems. The family-run company is very familiar with the challenges that startups

in the industry face. This is why, together with the client, tailored solutions based on a broad portfolio of existing and already-proven injection systems are developed quickly and efficiently.

Find out more about the opportunities for startups in the pharmaceutical and biotechnology industry, as well as MedTech startups, to bring new active ingredients onto the market with the innovative pen injection systems made by Haselmeier. Call us on +49 (0) 711 71 97 90 or send an e-mail to info@haselmeier.com



Wilhelm Haselmeier
GmbH & Co. KG

Dr. Fred Metzmann,
Chief Business Officer

Vaihinger Straße 48
70567 Stuttgart / Germany
Phone +49 711 719 78 163

Wilhelm Haselmeier GmbH & Co. KG, a business unit of the Haselmeier Group, is active in the medical field. Content provided in various formats provides general information about the status of developments and products and is aimed exclusively at a specialist audience. This information does not replace counseling.

www.haselmeier.com

Sitz: Stuttgart / registered court Stuttgart - HRA 2553 personally liable shareholder:
Gabriel Consult GmbH / General Manager: Gert Weber, Mark Bleckmann
Sitz: Stuttgart / registered court Stuttgart - HRB 11020

